22.80
-2.15%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Clal Biotechnology Industries
Its shares trade on Tel Aviv under the ticker CBI.TA. It has been listed since 30 May 2007. In the fiscal year to 31 December 2025, it reported revenue of ILS 835,000 and a net loss of ILS 13.3m. At that date it held total assets of ILS 41.8m and shareholders' equity of ILS 20.2m.
Clal Biotechnology Industries Ltd. is a holding company which, engages in life sciences and medical technology research and development. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The firm is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 May 2007
- Employees
- 194
- Website
- cbi.co.il ↗
Leadership
Pay as last reported
- Mr. Avraham FischerChairman of the Board, since 2003
- Dr. Julian AdamsPresident, Chief Scientific Officer
- Mr. Ofer GonenChief Executive Officer
- Mr. Assaf SegalVice President - Finance
- Ms. Orit LidorVice President, General Counsel
- Mr. Ofer GoldbergVice President
- Mr. Tomer BabaiDirector
- Dr. Gavriel BarabashDirector
- Mr. Isaac KohlbergDirector
- Ms. Nofar MalovaniDirector
- Dr. Aharon SchwartzDirector
- Mr. Shmuel RubinsteinExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clal Biotechnology Industries Ltd. has 194 employees focused on life sciences R&D.
- CBI's portfolio includes Andromeda Biotech for type 1 diabetes treatment.
- CBI's subsidiary CII is part of the IDB group, providing strong financial backing.
Weaknesses
- CBI is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII).
- CBI's portfolio companies operate at different R&D stages without clear timelines.
- CBI's business is limited to bio-pharmaceutical R&D with no diversification.
Opportunities
- CBI's investments in D-Pharm and Trombutech for ischemic stroke treatment present growth potential.
- CBI's portfolio includes Mediwound for burn and wound management, a growing market segment.
- CBI's focus on cancer treatments through Biokine, Biocancell, and CureTech aligns with global health priorities.
Threats
- CBI's reliance on CII for financial support creates dependency risks.
- CBI's portfolio companies face regulatory hurdles in bio-pharmaceutical development.
- CBI's limited employee count of 194 may hinder rapid scaling of R&D projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.